ライフサイエンスコーパス: alopecia areata

1 areata, whereas 39 of 44 controls developed alopecia areata.

2 r are candidate genes in the pathogenesis of alopecia areata.

3 lium, are similar to those observed in human alopecia areata.

4 gs regarding the use of these treatments for alopecia areata.

5 n our understanding of the genetic basis for alopecia areata.

6 ma, 0.03% for decubitus ulcer, and 0.01% for alopecia areata.

7 rheumatoid arthritis, atopic dermatitis, and alopecia areata.

8 sed in the treatment of warts, melanoma, and alopecia areata.

9 ied to advancing the therapeutic pipeline of alopecia areata.

10 rthritis, juvenile idiopathic arthritis, and alopecia areata.

11 ted in patients aged 12 years and older with alopecia areata.

12 he inflammation that targets anagen hairs in alopecia areata.

13 EC family kinase inhibitor, in patients with alopecia areata.

14 te derivative, SCD-153, for the treatment of alopecia areata.

15 urrently being explored for the treatment of alopecia areata.

16 irst-line agent for limited patchy childhood alopecia areata.

17 a novel high-incidence model for spontaneous alopecia areata.

18 ivilege as a key step in the pathogenesis of alopecia areata.

19 a contributing factor in the development of alopecia areata.

20 elogen effluvium, androgenetic alopecia, and alopecia areata.

21 gous genes potentially associated with human alopecia areata.

22 C57BL/6J mice do not develop alopecia areata.

23 supporting this locus as being important in alopecia areata.

24 eles of the IL-1RN and various phenotypes of alopecia areata.

25 er of skin grafts from mice with spontaneous alopecia areata.

26 ral chronic inflammatory diseases, including alopecia areata.

27 opic dermatitis, 0.97 (95% CI, 0.65-1.46) in alopecia areata, 0.90 (95% CI, 0.49-1.65) in vitiligo, 1

28 soriasis, 1.83 in atopic dermatitis, 0.94 in alopecia areata, 0.93 in vitiligo, 1.65 in HS and 1.53 i

29 odgkin's lymphoma (1.85[1.66-2.06], RD0.02), Alopecia Areata (1.77[1.71-1.83], RD0.2), Crohn's diseas

30 iditis, type 1 diabetes, coeliac disease and alopecia areata(1,2).

31 42, 3.61)], rosacea [2.85 (2.79, 2.92)], and alopecia areata [2.81 (2.61, 3.03)].

32 ndrogenetic alopecia (37.3 128.4, 46.1]) and alopecia areata (24.9 [17.2, 32.6]) were statistically s

33 uding atopic dermatitis [2.46 (2.40, 2.53)], alopecia areata [3.47 (3.24, 3.71)], contact dermatitis

34 We aimed to determine the risk of alopecia areata (AA) and vitiligo associated with atopic

35 Vitiligo and alopecia areata (AA) are common autoimmune conditions ch

36 The mechanisms driving alopecia areata (AA) are still unclear, hindering develo

37 yelash hair regrowth in patients with severe alopecia areata (AA) at week 36 of treatment.

38 Alopecia areata (AA) has a high prevalence worldwide and

39 Alopecia areata (AA) has been associated with multiple c

40 Treatments for alopecia areata (AA) have evolved over the decades from

41 However, vitiligo and alopecia areata (AA) have not been well characterized in

42 t has long been appreciated that episodes of alopecia areata (AA) have occurred after severely stress

43 Alopecia universalis is an uncommon form of alopecia areata (AA) involving hair loss over the entire

44 Alopecia areata (AA) is a chronic, nonscarring hair-loss

45 Alopecia areata (AA) is a common autoimmune disease resu

46 Alopecia areata (AA) is a common T cell-mediated disorde

47 Alopecia areata (AA) is a complex immune-mediated disord

48 Alopecia areata (AA) is a genetically determined, immune

49 Alopecia areata (AA) is a non-scarring inflammatory hair

50 Alopecia areata (AA) is among the most highly prevalent

51 Alopecia areata (AA) is among the most prevalent autoimm

52 Alopecia areata (AA) is an autoimmune disease characteri

53 Alopecia areata (AA) is an autoimmune disease defined by

54 Alopecia areata (AA) is an autoimmune disease of the hai

55 Alopecia areata (AA) is an autoimmune disease that attac

56 Alopecia areata (AA) is an autoimmune disease that targe

57 Alopecia areata (AA) is an autoimmune disorder of hair l

58 Alopecia areata (AA) is an autoimmune disorder of the ha

59 Alopecia areata (AA) is an autoimmune hair loss disorder

60 Alopecia areata (AA) is characterized by hair loss in pa

61 Alopecia areata (AA) is characterized by hair loss rangi

62 Alopecia areata (AA) is characterized by immune dysregul

63 Alopecia areata (AA) is characterized by nonscarring hai

64 Characterizing blood profile of alopecia areata (AA) is important not only for treatment

65 Alopecia areata (AA) is one of the most common forms of

66 Patients with alopecia areata (AA) may experience episodic disease fla

67 fficiently investigated frontiers in current alopecia areata (AA) pathobiology research, with an emph

68 Treatments for alopecia areata (AA) patients with extensive scalp hair

69 Pediatric alopecia areata (AA) prevalence and incidence data are k

70 Although alopecia areata (AA) severity is often defined by the de

71 Current measures of alopecia areata (AA) severity, such as the Severity of A

72 d atopic dermatitis (AD) among patients with alopecia areata (AA) using data from the Merative Market

73 Alopecia areata (AA), a non-scarring inflammatory hair l

74 skin from both humans and C3H/HeJ mice with alopecia areata (AA), a T cell-mediated autoimmune disea

75 Prevalences of alopecia areata (AA), alopecia totalis (AT), and alopeci

76 hown encouraging results in the treatment of alopecia areata (AA), an autoimmune form of hair loss, i

77 both anxiety and depression in patients with alopecia areata (AA), as well as a positive association

78 d cells-type 1 (ILC1) in the pathogenesis of alopecia areata (AA), because we found them to be signif

79 ority of patients under TNFi therapy develop alopecia areata (AA), the most common inflammatory hair

80 Alopecia areata (AA)-like hair loss in C3H/HeJ mice prov

81 (AU), the most severe and disabling types of alopecia areata (AA).

82 ) is increased in patients with vitiligo and alopecia areata (AA).

83 e Severity of Alopecia Tool (SALT) score for alopecia areata (AA).

84 eg) cells was reported to play a key role in alopecia areata (AA).

85 ry skin diseases (atopic dermatitis [AD] and alopecia areata [AA]).

86 Serum from 38 alopecia areata/AA, 41 atopic dermatitis/AD, 21 psoriasi

87 ly 1, 2015, and July 1, 2020, using keywords alopecia areata, acne, atopic dermatitis, lichen planus,

88 Alopecia areata affected and resistant mice were charact

89 Grafting alopecia areata affected C3H/HeJ mouse skin to littermat

90 In alopecia areata affected humans, 95 genes were significa

91 nic stimulus, but only lymph node cells from alopecia areata affected mice displayed an increased res

92 is results, lymph node and spleen cells from alopecia areata affected mice injected into normal haire

93 ion of CD4+ CD8+ expressing cells in chronic alopecia areata affected mice using monoclonal antibodie

94 Alopecia areata affected skin contained increased number

95 a is a cell-mediated autoimmune disease, but alopecia areata affected skin graft hosts may resist alo

96 Of 44 mice that received alopecia areata affected skin grafts but failed to devel

97 cia areata, only two of 22 receiving further alopecia areata affected skin grafts developed alopecia

98 utpatients clinic, 2 to 16 years of age with alopecia areata affecting at least 10% of scalp surface

99 Alopecia areata affects 1%-2% of the population and is h

100 Alopecia areata also has a major negative impact on qual

101 For comparison, skin biopsies from alopecia areata and androgenetic alopecia affected human

102 tries, patients aged 12 years and older with alopecia areata and at least 50% scalp hair loss were ra

103 ese therapeutic techniques for patients with alopecia areata and further refine which subtypes of the

104 and the immunopathogenic association between alopecia areata and hair color.

105 heumatic disease, thyroid disease, vitiligo, alopecia areata and inflammatory bowel disease) were sel

106 Among ASD subtypes, alopecia areata and Sjogren syndrome were consistently a

107 performed, in which the outcome variable was alopecia areata and the main predictor was natural hair

108 (including psoriasis, atopic dermatitis, and alopecia areata) and eight other immune-mediated disease

109 be associated with Crohn disease, psoriasis, alopecia areata, and leprosy.

110 s erythematosus, Sjogren syndrome, vitiligo, alopecia areata, and multiple sclerosis) and each indivi

111 into catagen, such as androgenetic alopecia, alopecia areata, and telogen effluvium.

112 lated conditions, such as atopic dermatitis, alopecia areata, and vitiligo, but there is a current US

113 ders, predominantly acne, atopic dermatitis, alopecia areata, and vitiligo, only 27.0% had T scores l

114 acne," "vitiligo," "seborrheic dermatitis," "alopecia areata," and "lichen planus." Diverse study pop

115 e relatives of 110 patients and 45 controls: alopecia areata, ankylosing spondylitis, dermatomyositis

116 Atopic dermatitis (AD) and alopecia areata are highly prevalent inflammatory skin/h

117 mice expressing this TCR develop spontaneous alopecia areata at nearly 100% incidence.

118 ation was observed between IL-1RN and patchy alopecia areata but it was not statistically significant

119 ed C3H/HeJ mouse skin to littermates induces alopecia areata, but high dietary soy oil reduces alopec

120 In a rodent model, alopecia areata can be induced in normal haired C3H/HeJ

121 to affect 2% of people over their lifetime, alopecia areata can present with a range of clinical fea

122 ons between atopic dermatitis, vitiligo, and alopecia areata, challenging previously established noti

123 ndividuals exhibited significantly decreased alopecia areata compared with those with light brown hai

124 lated or downregulated during onset of mouse alopecia areata consistent with an inflammatory cell-med

125 eczema, psoriasis, acne vulgaris, pruritus, alopecia areata, decubitus ulcer, urticaria, scabies, fu

126 onse towards the graft, it is suggested that alopecia areata develops as a consequence of an inapprop

127 ncing to successfully identify a significant Alopecia Areata disease-relevant gene, KRT82, and reveal

128 Seven PROMs (Scale of Alopecia Areata Distress, AAPPO, and all 5 symptom-based

129 Three PROMs (Scale of Alopecia Areata Distress, Alopecia Areata Quality of Lif

130 phenotype and functional status in extensive alopecia areata (EAA) scalp skin.

131 One patient with extensive alopecia areata experienced skin atrophy that resolved s

132 ale (DRS) was distributed using the National Alopecia Areata Foundation (NAAF) with the aim of assess

133 C3H/HeJ mice spontaneously develop alopecia areata from 5 mo of age and older in females an

134 Few treatments for alopecia areata have been well evaluated in randomized t

135 ssue from healthy controls and patients with alopecia areata, identifying diverse cell types of the h

136 f the first treatment for adults with severe alopecia areata in 2022 and for adolescents with severe

137 eata in 2022 and for adolescents with severe alopecia areata in 2023, with multiple investigational t

138 characterize a new high-incidence model for alopecia areata in C57BL/6J mice, the first to our knowl

139 , a gene that is known to be associated with alopecia areata in humans.

140 a(+)NKG2D(+) T effector memory cells mediate alopecia areata in part through Janus kinase (JAK) signa

141 nib might be a suitable treatment option for alopecia areata in patients who are candidates for syste

142 sults support a previously proposed model of alopecia areata in which immunity is directed against me

143 yloarthritis, inflammatory bowel disease and alopecia areata, in which stimulation of innate immunity

144 th rare damaging variants in 51 heterozygous Alopecia Areata individuals (6.01%), achieving genome-wi

145 Consensus was reached that the Alopecia Areata Investigator Global Assessment scale ade

146 These results suggest alopecia areata is a cell-mediated autoimmune disease, b

147 Alopecia areata is a common cause of non-scaring autoimm

148 Alopecia areata is a complex genetic disease that result

149 Alopecia areata is a suspected autoimmune hair loss dise

150 Alopecia areata is accompanied by Th2/Tc2 activation in

151 Alopecia areata is among the most prevalent autoimmune d

152 Alopecia areata is an autoimmune disease in which loss o

153 Alopecia areata is an autoimmune disease that targets ac

154 Alopecia areata is an idiopathic cause of hair loss with

155 Alopecia areata is an immune-mediated, nonscarring form

156 Alopecia areata is an inflammatory hair loss disease wit

157 Alopecia areata is characterised by non-scarring loss of

158 or efficacy of currently used treatments for alopecia areata is lacking.

159 Alopecia areata is less common, but may be distressing,

160 hed case-control study seem to indicate that alopecia areata is modulated by natural hair color, pref

161 Alopecia areata is one of the most frequent organ-restri

162 y loci have been implicated, the genetics of alopecia areata is still unclear.

163 ating question regarding the pathogenesis of alopecia areata is the potential linkage with the brain.

164 hrough Janus kinase (JAK) signaling and that alopecia areata might be treated with JAK inhibitors.

165 n = 96 138), atopic dermatitis (n = 30 418), alopecia areata (n = 17 889), vitiligo (n = 7735), or HS

166 um (n = 30), androgenetic alopecia (n = 52), alopecia areata (n = 17), and alopecia areata totalis/un

167 Alopecia areata (n=138) and clinically normal (n=214) mi

168 In considering all patients with any form of alopecia areata, no association was found with IL-1RN.

169 In addition, although alopecia areata often results in significant psychologic

170 a affected skin grafts but failed to develop alopecia areata, only two of 22 receiving further alopec

171 Alopecia areata onset could be inhibited in skin-grafted

172 areata affected skin graft hosts may resist alopecia areata onset through active counter-regulatory

173 ainly to the contribution from mild cases of alopecia areata [OR 1.48 (0.96, 2.29)], suggesting that

174 sociation between IL1-RN*1 allele and patchy alopecia areata (p =0.045).

175 an immune cell-mediated disease mechanism in alopecia areata pathogenesis and suggested targeting ant

176 Three PROMs (Alopecia Areata Patient Priority Outcomes [AAPPO], Alope

177 en phase, and its expression is decreased in Alopecia Areata patient skin and hair follicles.

178 d gene-level burden analyses approach on 849 Alopecia Areata patients compared to 15,640 controls.

179 Alopecia areata patients with and without concomitant at

180 , Alopecia Areata Quality of Life Index, and Alopecia Areata Patients' Quality of Life) were AA-speci

181 , Sjogren syndrome, Crohn disease, vitiligo, alopecia areata, pernicious anemia, ulcerative colitis,

182 to normal haired littermates transferred the alopecia areata phenotype.

183 In this paper, we analyzed alopecia areata probands in a family-based sample (n = 1

184 Treatment reduced skin pathology in alopecia areata, psoriasis, and atopic dermatitis, while

185 ee PROMs (Scale of Alopecia Areata Distress, Alopecia Areata Quality of Life Index, and Alopecia Area

186 to evaluate possible mechanisms involved in alopecia areata resistance.

187 Because alopecia areata resistant mice showed unimpaired respons

188 In contrast, alopecia areata resistant mouse skin did not display inc

189 CTLA4, CD44v variants, and FasL occurred in alopecia areata resistant mouse spleens.

190 KRT82 is identified as an Alopecia Areata risk gene with rare damaging variants in

191 1RN*2 allele was found to be associated with alopecia areata severity in a British case-control study

192 ia Areata Patient Priority Outcomes [AAPPO], Alopecia Areata Severity Self-Assessment, and Alopecia A

193 ASDs, including alopecia areata, Sjogren syndrome, vitiligo, cutaneous l

194 purported resistance locus) did not develop alopecia areata, supporting this locus as being importan

195 cia areata, but high dietary soy oil reduces alopecia areata susceptibility.

196 lopecia Areata Severity Self-Assessment, and Alopecia Areata Symptom Impact Scale) were based on both

197 mon skin diseases, ranging from psoriasis to alopecia areata to vitiligo to lupus erythematosus to at

198 results have been reported in patients with alopecia areata totalis (AT) or universalis (AU), the mo

199 h telogen effluvium (50.1 [33.9, 66.33]) and alopecia areata totalis/universalis (52.3 [23.1, 81.5])

200 ecia (n = 52), alopecia areata (n = 17), and alopecia areata totalis/universalis (n = 7).

201 and reactive lymphocytes may be effective in alopecia areata treatment.

202 ched by age and sex to 6692 controls without alopecia areata using 1:4 matching.

203 e, we identify rare variants contributing to Alopecia Areata using a whole exome sequencing and gene-

204 kin diseases, including lupus erythematosus, alopecia areata, vitiligo, and lichen planus.

205 ogist-recorded psoriasis, atopic dermatitis, alopecia areata, vitiligo, or hidradenitis suppurativa w

206 the case of dermatological diseases such as alopecia areata, vitiligo, psoriasis and atopic dermatit

207 women, and the mean (SD) age for those with alopecia areata was 46.9 (16.5) years.

208 Alopecia areata was associated with moderate (OR, 5.23;

209 Alopecia areata was identified based on having at least

210 Alopecia areata was significantly more common in individ

211 o investigate the role of the IL-1 system in alopecia areata we examined three biallelic polymorphism

212 rticaria, pruritus, scabies, cellulitis, and alopecia areata were underrepresented in CDSR when match

213 mice, and mice with and without spontaneous alopecia areata, were similarly processed.

214 opecia areata affected skin grafts developed alopecia areata, whereas 39 of 44 controls developed alo

215 Among these individuals, 1673 cases of alopecia areata with reported hair color were captured a

216 is characterized by loss of hair in patches (alopecia areata) with progression in some individuals to